Displaying results 1 - 3 of 3
EASL Studio S1 E1: Liver Cancer Awareness Month • Description Since 2020 EASL Studio has been a part of the International Liver Congress (ILC), bringing you the most up-to-date research live from the congress. But EASL Studio is evolving. EASL Studio is now a new platform through which we will be exploring hepatology every week, from every angle. Through live debates, interviews, and roundtable discussions, EASL Studio will be a chance to peak behind the scenes. Hear the expert’s opinion on the latest research. Discover what it’s like to be a young investigator. Meet the Nurses, the allied health professionals, and the patients they work with. Watch on-demand the first Session that was broadcasted on Wednesday 27 October 2021. Programme Time Title 00:00-04:12 Welcome and Introductions Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain 04:12-28:26 Topic 1: Raising awareness about Liver Cancer Nathalie Ganne-Carrié, Avicenne Hospital, France Peter Jepsen, University of Aarhus, Denmark 28:26-47:34 Topic 2: Liver Cancer Summit: Highlights from 2021 and what awaits us in 2022 Angela Lamarca, University of Manchester, United Kingdom Jean-Charles Nault, Avicenne Hospital, France 47:34-50:31 Closing remarks Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain
EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022 • Description The highlights of EASL's Liver Cancer Summit 2022 - What is practice changing right now and where are the current controversies? How do our experts interprete the new data on Immunotherapy in HCC and CCA, and what to expect in 2022: Upcoming trials, New combinations, New biomarkers Watch on-demand the session that was broadcast Friday 4 February 2022.
EASL Policy Dialogues Episode 3: Liver cancer: The risk of ignorance • Description In this third episode, the experts discuss the worrying burden of liver cancer in Europe and the political actions needed to invert the curve. How can deaths from liver cancer be prevented and how is EASL and the hepatology community working towards this goal? What is the European Union doing for cancer control, and which are the challenges?